Human Cancer Antigen 50 CLIA Kit​​​​​​​


The Human Cancer Antigen 50 CLIA Kit is a Chemiluminescence Immunoassay (CLIA) intended for the quantitative measurement of human Cancer Antigen 50 concentration in serum.
​​​​​​​For research use only. Not for use in diagnostics procedures.


The Human Cancer Antigen 50 CLIA Kit is designed, developed, and produced for the quantitative measurement of human CA50 level in serum samples. The assay utilizes a twosite “sandwich” technique with two antibodies that bind to different epitopes of CA50. Assay calibrators, controls, or patient serum samples are added directly to a reaction vessel together with magnetic particles antibody. The magnetic particles capture the CA50 in the form of “magnetic particles–CA50 antibody–CA50– acridinium ester CA50 antibody”. Materials bound to the solid beads are held in a magnetic field while unbound materials are washed away. Then trigger solutions are added to the reaction vessel, and light emission is measured with the ECL100 or ECL 25 analyzer. The relative light units (RLU) are proportional to the concentration of a CA50 in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve and reported in serum CA50 concentration.


Catalog no. SKT-067R
Target Human Cancer Antigen 50
Species Human
Method Sandwich CLIA
Tests Per Kit 100 tests
Detection Flash AE Chemiluminescence
Sensitivity / LLOD ≤2.50U/ml
Dynamic Range 2.50U/ml to 500 U/ml
Total Incubation Time 10 minutes
Sample Type Serum
Sample Volume 20 µL
Storage Temperature 2-8 °C

Selected Literature

​​​​​​​1. GrankviskK,LinngbergB,Rasmuson T. Evaluation of five glycoprotein tumor marks (CEA, CA50, CA19-9, CA125, CA 15-3) for the prognosis of renal cell carcinoma. Int J Cancer, 1997, 74: 233-236.
2. Diagnostic Value of Determination of Serum CEA, CA50 and CA19-9 in Gastrointestinal Cancers Medical Journal of Commu- nications 195-203.
​​​​​​​3. Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10ng/ml. IntUrolNephrol. 2007 Jul 6 34-85.
For research use only. Not for use in diagnostics procedures.